Oruka Therapeutics, Inc. (ORKA) was reiterated at Outperform by Wedbush analyst Martin Fan with a 12-month price target of $165, nearly triple the company's current share price of $63.90. The valuation is based on a sum-of-parts model projecting worldwide sales of its lead program ORKA-001 and ORKA-002, discounted to reflect development risk.
ORKA's pipeline is anchored by ORKA-001, an IL-23p19 antibody in psoriasis. The Phase 2a EVERLAST-A study has already shown strong efficacy, with 63.5% of patients achieving PASI 100 at Week 16. Longer-term follow-up data, including 28 weeks for all patients and 52 weeks for a subset, are expected in the second half of 2026. Analysts will be watching whether responses deepen and whether maintenance data could support once-yearly or as-needed dosing. A Phase 2b dose-ranging trial, EVERLAST-B, is underway with results anticipated in 2027 to support Phase 3 initiation.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.